Sylvester Comprehensive Cancer Center

What Sylvester Comprehensive Cancer Center does

Sylvester Comprehensive Cancer Center is the only National Cancer Institute (NCI)-designated Comprehensive Cancer Center in South Florida, operating as a not-for-profit academic division of the University of Miami Health System and the University of Miami Miller School of Medicine. Founded in 1973, the center delivers cancer diagnosis, treatment, and survivorship care across approximately 40 locations serving Miami-Dade, Broward, Palm Beach, and Collier Counties, with additional international patient services. Its research enterprise generated $360M in total research funding in FY25, including $178.8M in NIH funding across 1,761 active research projects and 1,138 clinical trials, and it hosts eight nationally top-25 NIH-funded departments.

Core research and clinical platforms include the Sylvester Data Portal — a cloud-based platform harmonizing clinical and genomic data from over 30,000 tumor samples via partnerships with Caris Life Sciences, Foundation Medicine, NeoGenomics, and Guardant Health; the GigaTIME AI model, which uses computer vision on bone marrow biopsy slides to predict multiple myeloma therapy response; the CIPHER-seq single-cell platform for simultaneous RNA and protein analysis; and theranostics programs for prostate and neuroendocrine tumors with expanding clinical trial indications. The September 2025 opening of the 244,000-square-foot Kenneth C. Griffin Cancer Research Building, organized around a scientific neighborhood model, doubled the center's research footprint.

Revenue derives from clinical care billed through insurance and self-pay, federal and foundation research grants (NIH, NCI, Hirshberg Foundation, Florida Cancer Innovation Fund), and institutional investment from the University of Miami — most notably a $30M five-year RISE commitment. Pricing for patient services includes a tiered financial assistance program capping eligibility at 400% of the Federal Poverty Guidelines. The center is governed by the University of Miami as part of its academic medical system, with no external private equity or venture ownership.

Name

Sylvester Comprehensive Cancer Center

Legal name

University of Miami Health System

Website

https://umiamihealth.org

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Sylvester Comprehensive Cancer Center is the only NCI-designated Comprehensive Cancer Center in South Florida, operating within the University of Miami Health System to deliver oncology care, run over 1,100 clinical trials, and develop AI and genomic research platforms serving regional and international cancer patients.

Ownership category

akta.pro rank

Product category

Comprehensive Cancer Care

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (622310), Outpatient Care Centers (6214), Offices of Physicians (62111)

SIC

Services-Specialty Outpatient Facilities, Nec (8093), Services-Health Services (8000), Services-General Medical & Surgical Hospitals, Nec (8062)

akta.pro primary industry

Oncology & Cancer Specialty Hospitals (HLAFAHAC)

akta.pro secondary industries

Ambulatory Oncology Centers (Outpatient Chemo/Radiation) (HLAFABAI), Nuclear Medicine Clinical Services & Therapy Centers (HLAIAGAI), Advanced Imaging & Specialty Radiology Centers (PET/CT, Nuclear Medicine, Interventional Radiology) (HLAFAKAB)

Keywords

• Oncology treatment services
• Cancer clinical trials
• Precision medicine oncology
• Cancer research programs
• Radiation therapy services

Headquarters

HQ city

Miami

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Clinical Care Revenue: Patient care services including cancer treatments, surgeries, immunotherapies, and therapeutic procedures billed through insurance and self-pay
2. Research Grants and Funding: Federal research funding from NIH ($178.8M), NCI designations, and private foundation grants including R01 grants, innovation funds, and seed grants
3. University of Miami Investment: $30M investment from University of Miami for basic science research over five years as part of RISE program

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Sylvester Comprehensive Cancer Center is the only NCI-designated Comprehensive Cancer Center in South Florida, providing cancer diagnosis, treatment, and clinical care across 40+ locations. The center integrates clinical care with academic research, conducting over 1,138 active clinical trials and operating research programs spanning multiple cancer types. It also develops proprietary technologies such as the GigaTIME AI model, CIPHER-seq single-cell platform, and Sylvester Data Portal to advance precision oncology.

Product overview

Sylvester Comprehensive Cancer Center is an NCI-designated cancer center offering a comprehensive portfolio of cancer research, treatment, and data platforms. Core offerings include the Sylvester Data Portal (SDP) for integrated clinical and genomic research, the GigaTIME AI model for bone marrow analysis, CIPHER-seq single-cell analysis platform, and theranostics radiation treatments. The center operates the Kenneth C. Griffin Cancer Research Building and conducts numerous clinical trials including virus-immunotherapy combinations, antibody therapies like linvoseltamab, and novel immunotherapy approaches for pancreatic cancer and other solid tumors.

Differentiator

Problem solved

Functional benefit

Brands

• Sylvester Data Portal (SDP): A cloud-based platform integrating clinical and genomic data from multiple sources for cancer research, with partnerships with Caris Life Sciences, Foundation Medicine, NeoGenomics, and Guardant Health.
• GigaTIME
• CIPHER-seq

Products and services

• Cancer Diagnosis and Treatment Services
• Clinical Trials Program
• Theranostics Treatment
• Sylvester Data Portal (SDP)
• GigaTIME AI Diagnostic Tool
• CIPHER-seq Single-Cell Analysis Platform
• Cancer Screening Services
• Precision Medicine Services
• Exercise and Lifestyle Intervention Programs
• International Patient Services

Quantifiable outcome

• 86.8% event-free survival at 18 months for low CD16 multiple myeloma patients on D-VRd therapy vs 28.6% on VRd alone
• +3 more outcomes

Named customers9 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability7 records

Feature7 records

Partnerships

14 partnerships are on record, tiered core and minor.

• HealthTree FoundationcoreStrategic or Co-development Partner · 21 May 2026Registry partnership providing 212 patient cohort for GigaTIME AI study analyzing bone marrow biopsy images to predict multiple myeloma treatment response
• Caris Life SciencescoreTechnology or Integration · 17 April 2026Genomic testing provider partnership for Sylvester Data Portal, contributing clinical and genomic data to the platform's integrated database of over 30,000 tumor samples
• Foundation MedicinecoreTechnology or Integration · 17 April 2026Genomic testing provider partnership contributing to Sylvester Data Portal's integrated clinical and genomic data platform
• NeoGenomicscoreTechnology or Integration · 17 April 2026Genomic testing provider partnership for Sylvester Data Portal integration, contributing tumor sample data to support precision medicine research
• Guardant HealthcoreTechnology or Integration · 17 April 2026Genomic testing provider partnership contributing liquid biopsy and genomic data to Sylvester Data Portal for cancer research
• Hirshberg FoundationcoreStrategic or Co-development Partner · 27 March 2026Provided $75,000 Seed Grant to Dr. Vineet Gupta for developing novel immunotherapy approach for pancreatic cancer using antibody-siRNA conjugate platform
• University of Miami Miller School of MedicinecoreStrategic or Co-development Partner · 26 March 2026$3 million award to train next generation of oncology researchers through UMGCCC training program
• Yale Cancer CenterminorStrategic or Co-development Partner · 13 March 2026Prior institutional affiliation of Dr. Mario Sznol, who contributed to landmark checkpoint inhibitor research before joining Sylvester
• National Cancer InstituteminorStrategic or Co-development Partner · 13 March 2026Prior institutional affiliation of Dr. Mario Sznol, who contributed to landmark checkpoint inhibitor research at NCI before joining Sylvester
• University of Miami Miller School of MedicinecoreStrategic or Co-development Partner · 3 February 2026RISE program earmarked $30 million over five years for basic science research, connecting medical students, trainees and junior faculty with research opportunities
• Jackson Health SystemcoreStrategic or Co-development PartnerClinical partnership combining UHealth's academic medical expertise with Jackson's public health network for patient care, education and research across Miami-Dade County
• Bruce W. Carter VA Medical CentercoreStrategic or Co-development PartnerCollaboration integrating UHealth physicians and researchers into VA health care system, combining clinical care, medical education and research to serve veterans in South Florida
• Hospital for Special SurgerycoreStrategic or Co-development PartnerPartnership bringing world-class musculoskeletal care to South Florida through collaboration with UHealth
• C4QIminorStrategic or Co-development PartnerCollaboration of NCI-designated cancer centers dedicated to advancing cancer care through shared data and best practices

Scale indicators12 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• MD Anderson Cancer Center: The leading NCI-designated Comprehensive Cancer Center in the US, offering the same combination of cancer research, clinical trials, and specialty inpatient/outpatient oncology care as Sylvester. Direct competitor for industry-sponsored trials, faculty recruitment, and national patient referrals.
• Memorial Sloan Kettering Cancer Center: Top-ranked NCI-designated cancer center with a parallel mix of translational research, precision medicine, and large clinical trial operations. Competes directly for federal funding, industry-sponsored studies, and complex cancer cases.
• Dana-Farber Cancer Institute: Harvard-affiliated NCI Comprehensive Cancer Center with strong emphasis on translational science and clinical trials in oncology. Comparable in structure (academic medical center), research output, and clinical trial portfolio.
• Moffitt Cancer Center: The only other NCI-designated Comprehensive Cancer Center in Florida, located in Tampa. Direct in-state competitor for patients, faculty, industry-sponsored trials, and Florida state funding.
• Fred Hutchinson Cancer Center: NCI-designated cancer center with a strong research and bone marrow transplant heritage. Overlaps with Sylvester in immunotherapy, precision medicine, and clinical trial activity.
• Winship Cancer Institute of Emory University: NCI-designated Comprehensive Cancer Center in the Southeast, similarly structured as an academic cancer center within a university health system. Competes for federal grants and Southeast regional referrals.
• UCSF Helen Diller Family Comprehensive Cancer Center: NCI-designated Comprehensive Cancer Center with comparable translational research, precision medicine, and clinical trial scale. Direct competitor for pharma-sponsored oncology programs and academic talent.
• Perlmutter Cancer Center (NYU Langone): NCI-designated Comprehensive Cancer Center within a large academic health system. Comparable research portfolio, clinical trial activity, and competitive positioning for federal funding.
• City of Hope Comprehensive Cancer Center: NCI-designated Comprehensive Cancer Center with a translational research focus similar to Sylvester, including cellular therapy and precision medicine. Competes for industry-sponsored trials and biotech partnerships.

Broad incumbents

• Mayo Clinic Comprehensive Cancer Center: NCI-designated comprehensive cancer center embedded in a multi-specialty health system. Competes with Sylvester for complex oncology cases and industry trials, but as part of a much broader clinical enterprise.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/SylvesterCancer
• YouTubeyoutube.com/channel/UCrR8h8xHhR5qBNjT0bNQKMw
• Facebookfacebook.com/SylvesterCancer
• LinkedInlinkedin.com/company/sylvester-comprehensive-cancer-center
• Instagraminstagram.com/umiamihealth
• TikToktiktok.com/@umiamihealth

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries4 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sylvester Comprehensive Cancer Center